secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2023-01-05T23:59:59+00:00
Accession:  0001437749-23-000499
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex enters exclusive license with University of Pittsburgh for Type 2 diabetes gene therapy
--------------------------------------------------------------------------------

- Genprex (GNPX) licensed worldwide exclusive rights to gene therapy using Pdx1 and MafA genes for Type 2 diabetes from University of Pittsburgh.
- License includes milestone payments up to $4.0 million, single-digit royalties, and a low double-digit share of sublicense income.
- The GPX-003 technology aims to rejuvenate beta cells to increase insulin expression; preclinical data accepted for oral presentation at ATTD 2023.
- This is the third diabetes technology license from University of Pittsburgh in 2022, covering both Type 1 (GPX-002) and Type 2 diabetes programs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/0001437749-23-000499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774923000499/gnpx20230103_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-000499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer